Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX-200 in Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)
NCT04637282Phase 3Withdrawn
- Sponsor
- Polaryx Therapeutics
- Start
- Nov 2026
- Primary completion
- Dec 2026
01
Overview
A Phase 3 trial of PLX-200 in juvenile neuronal ceroid lipofuscinosis (JNCL), sponsored by Polaryx Therapeutics. Planned start Nov 2026; status: withdrawn.
02
Drugs
PLX-200
03
Conditions
juvenile neuronal ceroid lipofuscinosis (JNCL)
Beyond the preview
Go deeper on NCT04637282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637282.